Labcorp Completes Acquisition of Toxikon Corporation
03 Dezembro 2021 - 2:34PM
Business Wire
Labcorp (NYSE: LH), a leading global life sciences company,
today announced that it has closed its acquisition of Toxikon
Corporation, a contract research organization delivering
best-in-class nonclinical testing services. The addition of Toxikon
to Labcorp Drug Development bolsters Labcorp’s strong nonclinical
development portfolio, and creates a strategic footprint for the
company to partner with pharmaceutical and biotechnology clients in
the Boston, Mass., area.
The definitive agreement for the transaction was announced on
Nov. 18. Specific terms were not disclosed.
About Labcorp
Labcorp is a leading global life sciences company that provides
vital information to help doctors, hospitals, pharmaceutical
companies, researchers, and patients make clear and confident
decisions. Through our unparalleled diagnostics and drug
development capabilities, we provide insights and accelerate
innovations to improve health and improve lives. With more than
70,000 employees, we serve clients in more than 100 countries.
Labcorp (NYSE: LH) reported revenue of $14 billion in FY 2020.
Learn more about Labcorp at www.Labcorp.com, or follow us on
LinkedIn and Twitter @Labcorp.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20211203005484/en/
Labcorp Contacts: Media: Christopher Allman-Bradshaw –
336-436-8263 Media@Labcorp.com Investors: Chas Cook – 336-436-5076
Investor@Labcorp.com
Laboratory Corporation o... (NYSE:LH)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024
Laboratory Corporation o... (NYSE:LH)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024
